PolyPid (PYPD) to Release Quarterly Earnings on Wednesday

PolyPid (NASDAQ:PYPD) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, November 13th. Analysts expect PolyPid to post earnings of ($1.07) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

PolyPid (NASDAQ:PYPD) last released its earnings results on Wednesday, August 14th. The company reported ($1.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.51) by $0.26. On average, analysts expect PolyPid to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

PolyPid Price Performance

PolyPid stock opened at $3.34 on Wednesday. PolyPid has a 1 year low of $2.95 and a 1 year high of $9.20. The firm has a 50 day moving average price of $3.48 and a 200 day moving average price of $3.87. The company has a market cap of $16.02 million, a price-to-earnings ratio of -0.33 and a beta of 1.31. The company has a debt-to-equity ratio of 1.95, a quick ratio of 0.95 and a current ratio of 0.95.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Craig Hallum initiated coverage on PolyPid in a research report on Monday. They set a “buy” rating and a $10.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of PolyPid in a report on Wednesday, October 2nd.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.